Animol Discovery is a technology company.
Animol Discovery has raised $40.0M across 2 funding rounds.
Animol Discovery has raised $40.0M in total across 2 funding rounds.
Animol Discovery is a biopharmaceutical company developing novel small molecule pharmaceuticals for unmet needs in veterinary medicine, targeting both companion and farm animals.[1][2][3] It builds a proprietary pipeline of active pharmaceutical ingredients (APIs) addressing conditions like anti-parasitics and chronic diseases, using a platform combining genomics analysis, DNA-encoded libraries (DELs), AI/machine learning, and computational chemistry to accelerate discovery of safer, more effective drugs.[1][2][3][4] The company serves veterinary patients by solving gaps in current treatments, where existing drugs fall short in efficacy or safety, and recently raised $34 million in Series B financing to advance its pipeline through clinical development.[2]
Animol Discovery was co-founded by Andrew Calabrese, Ph.D., a scientific expert with extensive experience in biotech startups across human health, animal health, and crop protection.[3] Calabrese, previously at Pfizer and Celgene, invented drug candidates like Cligcosiban™ (in late-stage human trials) and led animal health products such as Aviax™ (anticoccidial) and TreoAce™ (endectocide commercialized in under three years).[3] The idea emerged from recognizing unmet veterinary needs and leveraging Calabrese's R&D expertise from concept to commercialization, building a team of animal health industry veterans.[3] Early momentum includes building a proprietary pipeline and securing Series B funding led by Novalis Lifesciences, with participation from Finistere Ventures and Anterra Capital.[2]
Animol Discovery stands out in veterinary drug discovery through:
Animol Discovery rides the convergence of AI, DELs, and computational tools transforming drug discovery, particularly in underserved veterinary markets where human pharma adaptations often underperform.[1][4] Timing aligns with rising demand for animal health innovations amid growing pet ownership, sustainable farming, and regulatory pushes for better livestock welfare, amplifying market forces like biotech funding in agtech/vetmed.[2] It influences the ecosystem by pioneering animal-specific platforms, potentially lowering barriers for novel APIs and inspiring similar tech stacks in biotech, bridging gaps between human and veterinary R&D.[3][5]
Animol Discovery is poised to advance its pipeline into clinical trials with Series B capital, targeting breakthroughs in anti-parasitics and chronic veterinary conditions.[2] Trends like AI-driven screening and expanded DEL applications will accelerate its momentum, while partnerships could fast-track commercialization.[1][4] Its influence may grow by setting standards for tech-enabled vet pharma, potentially capturing share in a market hungry for tailored, effective treatments—ultimately delivering on its mission to innovate until every animal is well.[1]
Animol Discovery has raised $40.0M in total across 2 funding rounds.
Animol Discovery's investors include Anterra Capital, F-Prime Capital Partners.
Animol Discovery has raised $40.0M across 2 funding rounds. Most recently, it raised $34.0M Series B in July 2022.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Jul 1, 2022 | $34.0M Series B | Anterra Capital, F-Prime Capital Partners | |
| Dec 1, 2019 | $6.0M Series A | Anterra Capital, F-Prime Capital Partners |